Drilldown: Medicines
Use the filters below to narrow your results.
generic:
brand:
classes:
Beta Blocker (1) ·
Cardioselective (β1) (1) ·
Combined cholinesterase inhibitor + NMDA antagonist (1) ·
[[:Category:5-alpha-reductase_inhibitors|5α-reductase inhibitor]] (1) ·
[[:Category:Androgen_modulators|Androgen modulator]] (1) ·
[[:Category:Antiarrhythmics|Antiarrhythmic (Vaughan-Williams class IC)]] (1) ·
[[:Category:Antibacterials|Antibacterial]] (1) ·
[[:Category:Antihyperglycemic_agents|Antihyperglycemic agent]] (1) ·
[[:Category:BPH_treatments|Benign prostatic hyperplasia treatment]] (1) ·
[[:Category:DPP-4_inhibitors|DPP-4 inhibitor]] (1) ·
[[:Category:Fluoroquinolones|Fluoroquinolone antibiotic]] (1) ·
[[:Category:Incretin_modulators|Incretin pathway modulator]] (1)
mechanism:
None (2) ·
Cardioselective β1-adrenergic antagonist. Selectivity is dose-dependent and partially lost at higher doses. (1) ·
Donepezil: reversible AChE inhibitor, increases synaptic acetylcholine. Memantine: uncompetitive low-affinity NMDA receptor antagonist, dampens pathological glutamate overactivation while preserving normal synaptic signaling. Targets two distinct mechanisms in Alzheimer's. (1) ·
'"`UNIQ--vote-00000D7A-QINU`"' Substantial QT-interval prolongation — the most QT-prolonging fluoroquinolone — limits use in patients on other QT-prolonging agents or with electrolyte abnormalities'"`UNIQ--ref-00000D7B-QINU`"'. (1) ·
'"`UNIQ--vote-0000113A-QINU`"' Concomitant β-blocker or CCB is required when used for AF to prevent 1:1 atrial flutter conduction (flecainide can slow atrial rate to a level where AV conduction allows dangerous ventricular rates). CYP2D6 substrate'"`UNIQ--ref-0000113B-QINU`"'. (1)
uses:
'"`UNIQ--vote-00000468-QINU`"' (1) ·
'"`UNIQ--vote-000004F5-QINU`"', '"`UNIQ--vote-000004F6-QINU`"', '"`UNIQ--vote-000004F7-QINU`"', '"`UNIQ--vote-000004F8-QINU`"', '"`UNIQ--vote-000004F9-QINU`"' (1) ·
'"`UNIQ--vote-0000052E-QINU`"', '"`UNIQ--vote-0000052F-QINU`"', '"`UNIQ--vote-00000530-QINU`"' (1) ·
'"`UNIQ--vote-00000D7C-QINU`"', '"`UNIQ--vote-00000D7D-QINU`"', '"`UNIQ--vote-00000D7E-QINU`"', '"`UNIQ--vote-00000D7F-QINU`"', '"`UNIQ--vote-00000D80-QINU`"', '"`UNIQ--vote-00000D81-QINU`"' (1) ·
'"`UNIQ--vote-0000113C-QINU`"', '"`UNIQ--vote-0000113D-QINU`"', '"`UNIQ--vote-0000113E-QINU`"' (1) ·
'"`UNIQ--vote-0000117B-QINU`"' (1)
starting dose:
25–50 mg BID (tartrate); 25–100 mg daily (succinate); 12.5 mg daily in HFrEF (1) ·
400 mg PO/IV once daily (1) ·
5 mg PO daily for BPH; 1 mg PO daily for androgenetic alopecia (1) ·
5 mg PO once daily (no renal dose adjustment, unlike sitagliptin) (1) ·
50 mg PO BID; titrate to 100-200 mg BID; pill-in-pocket 200-300 mg PO single dose for AF conversion (1) ·
For patients already stable on memantine 28 mg/d + donepezil 10 mg/d, switch to one capsule daily of equivalent strength (1)
preparations:
1 mg, 5 mg tablets (1) ·
400 mg tablets; 400 mg/250 mL IV; 0.5% ophthalmic solution (1) ·
5 mg tablets; combination with metformin (1) ·
50, 100, 150 mg tablets (1) ·
7/10, 14/10, 21/10, 28/10 mg ER capsules (memantine ER / donepezil) (1) ·
Tartrate: 25, 50, 100 mg tabs; 1 mg/mL IV. Succinate ER: 25, 50, 100, 200 mg. (1)
fda max: (Click arrow to add another value)
routes:
onset:
1–2 h (PO); immediate (IV) (1) ·
AF conversion within hours of single PO dose (1) ·
BPH symptom improvement at 3-6 months; prostate volume reduction over 6-12 months; hair regrowth at 6-12 months (1) ·
Component effects accumulate over weeks (1) ·
Hours (1) ·
Postprandial glucose effect within days; HbA1c by 12 weeks (1)
duration:
halflife:
3–7 h (1) ·
~12 hours (effective); terminal much longer'"`UNIQ--ref-0000117C-QINU`"' (1) ·
~12 hours'"`UNIQ--ref-00000D82-QINU`"' (1) ·
~14 hours (adults); longer in elderly and renal impairment'"`UNIQ--ref-0000113F-QINU`"' (1) ·
~5-6 hours in young men, ~8 hours in elderly'"`UNIQ--ref-00000531-QINU`"' (1) ·
~60–80 h (memantine); ~70 h (donepezil) (1)
bioavailability:
pregnancy:
'''Avoid in pregnancy where alternatives exist''' (animal cartilage toxicity).<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
'''Pregnant individuals should not handle crushed/broken tablets''' (skin absorption risk); can cause hypospadias in male fetus. Not used in pregnancy.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Category C (1) ·
Limited data; switch to insulin where feasible.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Not relevant (geriatric problem) (1) ·
Use in fetal SVT (transplacental antiarrhythmic therapy) is established; otherwise weigh against alternatives.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
legal:
Rx-only in US (2) ·
[[USLegal:Prescription only|Rx-only]] in US (2) ·
[[USLegal:Prescription only|Rx-only]] in US. '''Contraindicated in structural heart disease''' — CAST trial (1989) showed increased mortality from class IC agents in patients with prior MI; modern use is limited to structurally normal hearts'"`UNIQ--ref-00001141-QINU`"' (1) ·
[[USLegal:Prescription only|Rx-only]] in US. Carries the same fluoroquinolone-class '''Boxed Warnings''' as ciprofloxacin/levofloxacin'"`UNIQ--ref-00000D84-QINU`"' (1)
Showing below up to 6 results in range #1 to #6.